Request Deal Involvement
Neopharmed Gentili to acquire the European business of ORLADEYO from BioCryst Pharmaceuticals for $264m.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
financial advisors
Centerview Partners
legal advisors
White & Case
legal advisors
Skadden Arps Slate Meagher & Flom
financial advisors
Bank of America
financial advisors
TD Cowen
or
Principals
target
ORLADEYO (BEROTRALSTAT BUSINESS)
bidder
NEOPHARMED GENTILI
vendor
BIOCRYST PHARMACEUTICALS
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite